Hyperlipoproteinemia, Atherosclerosis and Gemfibrozil

Publisher Website
Google Scholar
Abstract
Gemfibrozil (CL719,2,2-dimethyl-5-(2,5-xylyloxy) valeric acid) is a substituted phenoxy alkyl acid which decreases lipids in hyperlipidemia subjects [prone to atherosclerosis]. A short term study using 1200 mg gemfibrozil/day demonstrated reduction in total serum cholesterol, triglyceride and apo lipoprotein B levels, and a concomitant rise in HDL [high density lipoprotein] cholesterol levels. The drug had a more pronounced effect on triglyceride than cholesterol; it had few side effects and the effect was sustained. Gemfibrozil, compared to placebo, lowered plasma cholesterol, triglyceride and VLDL [very low density lipoprotein] levels and raised HDL levels.